Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel monotherapy or first adjunctive therapy in epilepsy
2017-001180-20Phase 4
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of perampanel in epilepsy, Focal Onset Epilepsy and generalized tonic-clonic seizure (GTCS) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Retention rate at 3 months, Retention rate at 6 months and 2 more.
02
Drugs
perampanel
03
Conditions
epilepsyFocal Onset Epilepsygeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2017-001180-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001180-20.